Redhill Biopharma RDHL 深 沪
等待开盘 05-28 09:30:00 美东时间
1.01
0.000
0.00%
华盛通- 最 高1.09
- 今 开1.02
- 成交量 11.93万股
- 最 低 0.99
- 昨 收 1.01
- 总市值 524.32万
- 52周最高 3.3099
- 市盈率 静 --
- 换手率 2.30%
- 52周最低 0.7101
- 委 比 -76.36%
- 总股本 519.13万
- 历史最高 22220.00
- 量 比 2.12
- 振 幅 9.90%
- 历史最低 0.7101
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies
04-30 19:12
Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly earnings of $0.00 per share. The company reported $286.000 thousand in sales this quarter. This is a 96.44 percent decrease over sales of $8.043 million the same period
04-27 20:14
RedHill Presents New Preclinical Showing Effects Of Opaganib As Potential Add-On Therapy In Models Of Retinoblastoma And Triple-Negative Breast Cancer At AACR Annual Meeting.
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of
04-22 20:06
RedHill Biopharma Says Full Sales And Operational Launch Of Talicia, Under Joint Commercialization Agreement Between Talicia And Cumberland Pharmaceuticals Has started
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled
02-25 20:11
What's Going On With Redhill Biopharma Stock On Tuesday?
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.
01-06 23:26
RedHill Biopharma shares are trading higher after the company announced development progress for RHB-102.
RedHill Biopharma shares are trading higher after the company announced develop...
01-05 23:44
Market-Moving News for January 5th
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
01-05 20:44
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroen...
01-05 20:00
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, wit...
2025-12-15 20:00
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced th...
2025-12-01 20:00
